On the origins of islands

Theoretical and Experimental Linguistic

Properties of Sarychev sulphate aerosols over the Arctic

Aerosols from the Sarychev Peak volcano entered the Arctic region less than a week after the strongest SO2 eruption on June 15 and 16, 2009 and had, by the second week in July, spread out over the entire Arctic region. These predominantly stratospheric aerosols were determined to be sub-micron in size and inferred to be composed of sulphates produced from the condensation of SO2 gases emitted during the eruption. Average (500 nm) Sarychev-induced stratospheric optical depths over the Polar Environmental Atmospheric Research Laboratory (PEARL) at Eureka, Nunavut, Canada were found to be between 0.03 and 0.05 during the months of July and August, 2009. This estimate, derived from sunphotometry and integrated lidar backscatter profiles was consistent with averages derived from lidar estimates over Ny-Ålesund (Spitsbergen). The Sarychev SOD e-folding time at Eureka, deduced from lidar profiles, was found to be approximately 4 months relative to a regression start date of July 27. These profiles initially revealed the presence of multiple Sarychev plumes between the tropopause and about 17 km altitude. After about two months, the complex vertical plume structures had collapsed into fewer, more homogeneous plumes located near the tropopause. It was found that the noisy character of daytime backscatter returns induced an artifactual minimum in the temporal, pan-Arctic, CALIOP SOD response to Sarychev sulphates. A depolarization ratio discrimination criterion was used to separate the CALIOP stratospheric layer class into a low depolarization subclass which was more representative of Sarychev sulphates. Post-SAT (post Sarychev Arrival Time) retrievals of the fine mode effective radius (reff,f) and the logarithmic standard deviation for two Eureka sites and Thule, Greenland were all close to 0.25 μm and 1.6 respectively. The stratospheric analogue to the columnar reff,f average was estimated to be reff,f(+) = 0.29 μm for Eureka data. Stratospheric, Raman lidar retrievals at Ny-Ålesund, yielded a post-SAT average of reff,f(+) = 0.27 μm. These results are ~ 50% larger than the background stratospheric-aerosol value. They are also about a factor of two larger than modeling values used in recent publications or about a factor of five larger in terms of (per particle) backscatter cross section

Evidence for a Decline in Northern Quebec (Nunavik) Belugas

belugas were present at the surface in the offshore areas of James Bay and Hudson Bay, respectively. An additional 39 animals were observed in estuaries during the coastal survey, resulting in an index estimate of 1194 (SE = 507) in eastern Hudson Bay. No belugas were observed in Ungava Bay. Observations from systematic surveys conducted in 1993 and 2001 were analyzed using both line-transect and strip-transect methods to allow comparisons with the strip-transect survey conducted in 1985. A population model incorporating harvest information and fitted to the aerial survey data indicates that the number of belugas in eastern Hudson Bay has declined by almost half because of high harvest levels. Subsistence harvest levels must be reduced significantly if this population is to recover. Key words: beluga, aerial survey, Nunavik, harvesting, northern Quebec, abundance RÉSUMÉ. Des relevés aériens systématiques de bélugas (Delphinapterus leucas) par échantillonnage en ligne ont été effectué

The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency

Abstract Background The autosomal recessive disorder N-acetylglutamate synthase (NAGS) deficiency is the rarest defect of the urea cycle, with an incidence of less than one in 2,000,000 live births. Hyperammonemic crises can be avoided in individuals with NAGS deficiency by the administration of carbamylglutamate (also known as carglumic acid), which activates carbamoyl phosphatase synthetase 1 (CPS1). The aim of this case series was to introduce additional cases of NAGS deficiency to the literature as well as to assess the role of nutrition management in conjunction with carbamylglutamate therapy across new and existing cases. Methods We conducted retrospective chart reviews of seven cases of NAGS deficiency in the US and Canada, focusing on presentation, diagnosis, medication management, nutrition management, and outcomes. Results Five new and two previously published cases were included. Presenting symptoms were consistent with previous reports. Diagnostic confirmation via molecular testing varied in protocol across cases, with consecutive single gene tests leading to long delays in diagnosis in some cases. All patients responded well to carbamylglutamate therapy, as indicated by normalization of plasma ammonia and citrulline, as well as urine orotic acid in patients with abnormal levels at baseline. Although protein restriction was not prescribed in any cases after carbamylglutamate initiation, two patients continued to self-restrict protein intake. One patient experienced two episodes of hyperammonemia that resulted in poor long-term outcomes. Both episodes occurred after a disruption in access to carbamylglutamate, once due to insurance prior authorization requirements and language barriers and once due to seizure activity limiting the family’s ability to administer carbamylglutamate. Conclusions Follow-up of patients with NAGS deficiency should include plans for illness and for disruption of carbamylglutamate access, including nutrition management strategies such as protein restriction. Carbamylglutamate can help patients with NAGS deficiency to liberalize their diets, but the maximum safe level of protein intake to prevent hyperammonemia is not yet known. Patients using this medication should still monitor their diet closely and be prepared for any disruptions in medication access, which might require immediate dietary adjustments or medical intervention to prevent hyperammonemia